ArticleCommunications biology2025
Analysis of biased allelic enhancer activity of schizophrenia-linked common variants.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genomic language model for predicting enhancers and their allele-specific activity in the human genome.Bioinformatics (Oxford, England) · 2026Article
- Analysis of biased allelic enhancer activity of schizophrenia-linked common variants.Communications biology · 2025Article
- IgG/IgM-coated gut microbiota in schizophrenia: associations with inflammation disease activity.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Schizophrenia is a neuropsychiatric disorder with heritability estimates between 60% and 80%. Although genome-wide association studies have identified many genetic loci linked to the disorder, most of these are noncoding variants whose functional impacts are not well understood. To bridge this gap, we prioritized potential functional variants linked to schizophrenia by utilizing a human brain epigenomic roadmap. We assessed the regulatory activity of these variants using an adapted STARR-seq screening method across four cell lines: Neuro-2a, SH-SY5Y, HEK-293T, and PC-12. Furthermore, we pinpointed candidate target genes through functional characterization and investigated their roles using zebrafish models. Our study identified 351 candidate single nucleotide polymorphisms (SNPs). Among these, 46 SNPs exhibited biased allelic enhancer activity, termed baaSNPs, with notable cell-type specificity. Chromatin interaction profiling and expression quantitative trait loci analyses linked these baaSNPs to 217 candidate target genes, and pathway enrichment analysis indicated that these genes are involved in critical neurological processes such as synaptic transmission and GABAergic signaling. One baaSNP in particular, rs13072690, showed regulatory effects across all examined cell lines and was associated with reduced expression of the PCCB gene in multiple brain regions. Heterozygous pccb knockout zebrafish exhibited abnormal behaviors, including hyperactivity, increased anxiety-like responses, and social deficits. In conclusion, our study demonstrates a valuable strategy for functionally annotating putative risk variants, complementing epigenetic approaches by providing insights into the regulatory potential of noncoding variants associated with schizophrenia. These findings offer promising candidates for further research into the underlying mechanisms of the disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.